Ann: Chairman's Address to the 2019 Annual General Meeting, page-2

23 July 2019
NTCELL® Parkinson’s trial – 2 year data analysis shows successful outcome
“Although successful, the small numbers in the trial necessitate a confirmative larger Phase III study. LCT, with specialist input from its expert Medical Advisory Board, is exploring the feasibility of a further study as it would require additional resources and clinical study design.”
7^th November 2019
Chairman’s Address to the 2019 Annual General Meeting
“We are currently exploring whether it would be possible to carry out a further clinical trial with NTCELL at this earlier stage of Parkinson’s disease. New Zealand is not a possible site for such a study given the number of patients required. In addition to the agreement of patients, neurologists, neurosurgeons and regulators, it would require more than $10 million of additional funding. So, you will understand why the Board is cautious about taking such a step, and is doing due diligence, initially with the science, then the venue, and how to raise sufficient funds.”

How long does it take to “explore”? Have you found a venue, worked out the science (please say yes!), had any interest in potential investors/partners? Is it a no go? Anything?
No point asking LCT, but I suspect they read these posts. LCT, if you want investors to show interest in your company, try to be a little more proactive and give us updates rather than telling us you are exploring.